alexa Treatment of Depression in Patients under Breast Cancer
ISSN: 2157-7609

Journal of Drug Metabolism & Toxicology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Short Communication

Treatment of Depression in Patients under Breast Cancer Therapy: Antidepressant-Tamoxifen Drug Interactions

Carlos Clayton Torres Aguiar*, João Vicente Augusto Aguiar and Marcelo Gondim Rocha

University of Fortaleza (UNIFOR), Fortaleza, Ceará, Brazil

*Corresponding Author:
Carlos Clayton Torres Aguiar
Professor in the Medicine Course
University of Fortaleza (UNIFOR)
Fortaleza, Ceará, Brazil
Tel: (85) 34773676
E-mail: [email protected]

Received date: April 22, 2017; Accepted date: May 10, 2017; Published date: May 17, 2017

Citation: Aguiar CCT, Aguiar JVA, Rocha MG (2017) Treatment of Depression in Patients under Breast Cancer Therapy: Antidepressant- Tamoxifen Drug Interactions. J Drug Metab Toxicol 8:228. doi: 10.4172/2157-7609.1000228

Copyright: © 2017 Aguiar CCT, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

The hormone therapy with tamoxifen is used in patients with breast cancer. The tamoxifen mechanism of action is based on the antagonist action of selective estrogen receptors. Depression and anxiety are psychiatric disorders which frequently coexist in patients with breast cancer. In the last decades, there has been an increase in the use of antidepressants. This literature review aims to provide a general view of pharmacokinetic knowledge of drug interactions between tamoxifen and antidepressants. Since tamoxifen is metabolized by CYP2D6, the use of antidepressants that are inhibitors of this is enzyme, such as paroxetine, fluoxetine and bupropion must be avoided. Based on cytochrome p450 drug interactions, it can be concluded that the use of citalopram, escitalopram, desvenlafaxine and venlafaxine are safe and effective treatment unlikely to alter tamoxifen efficacy.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords